Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Summit Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc.

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical company focused on developing patient-friendly cancer therapies, primarily in oncology. Its core product, ivonescimab, is a bispecific antibody targeting PD-1 and VEGF, designed to improve cancer treatment outcomes. The company advances its pipeline through clinical trials and strategic licensing, aiming to become a leader in innovative, immuno-oncology medicines for global markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Summit Therapeutics Inc.

1
1
Summit Therapeutics Inc. Summit Therapeutics Reports $189.4 Million Net Loss and Increased Operating Expenses

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Summit Therapeutics Inc. Summit Therapeutics Reports $1.08 Billion Loss for Fiscal Year 2025 Amid R&D Investments

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Summit Therapeutics Inc. Summit Therapeutics Reports $231.8 Million Net Loss in Latest Quarter Amid Increased R&D Expenses

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
Summit Therapeutics Inc. Summit Therapeutics Reports $565.7 Million Net Loss and Faces Funding Challenges

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Summit Therapeutics Inc. Summit Therapeutics Reports $62.9 Million Net Loss in Q1 2025, Expands License Agreement with Akeso

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Summit Therapeutics Inc. Summit Therapeutics Reports $221.3 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Summit Therapeutics Inc. Summit Therapeutics Reports Significant Asset Growth, Increased Losses Amid Ongoing Investment in Ivonescimab Clinical Trials

Via official filing (AI summary) | over 1 year ago | 0 comments